(AEMD) Aethlon Medical - Ratings and Ratios

Aethlon Medical, Inc. is a medical technology company specializing in the development of innovative therapeutic devices designed to address life-threatening conditions, including cancer and infectious diseases. The companys flagship product, Hemopurifier, is a first-of-its-kind biofiltration platform intended to remove cancer-promoting exosomes and other harmful particles from the blood. This technology is being explored for its potential in treating various cancers, viral infections, and as a supportive measure in organ transplantation procedures. Headquartered in San Diego, California, Aethlon Medical has been at the forefront of medical innovation since its inception in 1984.

Based on the provided data, Aethlon Medicals stock (NASDAQ:AEMD) is expected to face challenges in the next three months. Technically, the stock is in a bearish trend as the price ($0.45) is below both the 20-day ($0.55) and 50-day ($0.64) moving averages. The 200-day moving average ($0.48) further indicates a downward trajectory. The average true range (ATR) of $0.06 suggests low volatility, which may limit significant price movements. From a fundamental perspective, the companys market capitalization of $6.50M reflects its micro-cap status, which often correlates with higher investment risk. The forward P/E ratio of 0.21 indicates potential undervaluation, but the negative return on equity (-0.22) raises concerns about profitability. The price-to-book ratio of 1.67 suggests the stock may be fairly valued relative to its book value, though the price-to-sales ratio of 2.37 points to a premium compared to its revenue generation. Overall, while there may be opportunities for long-term growth, short-term stability appears uncertain.